Exogenous reproductive hormone use in breast cancer survivors and previvors.

Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol. 2018 Jan 23;: Authors: Vaz-Luis I, Partridge AH Abstract Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure for both previvors and survivors. We found these data to be hampered by small cohort sizes, heterogeneous patient populations, and limited study designs, highlighting a great need to conduct further research with the aim of enabling better-informed patient management. PMID: 29358778 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research

Related Links:

From time to time I have commented on the controversies over cancer screening. Most people assume that screening is an unqualified good, that early detection of cancer saves lives. Whenever some panel proposes recommending less screening, we hear screaming and yelling from advocates who claim they are trying to " ration " health care to save money at the expense of people's lives.In fact,as a bunch of Australians and a Minnesotan explain in BMJ, there are a few conditions called " cancer " that you are better off not treating, or perhaps treating very conservatively. These include what is called ductal ...
Source: Stayin' Alive - Category: American Health Source Type: blogs
AbstractMammographic density (MD) is a strong independent risk factor for breast cancer. It has been suggested that breast cancer is related to the exposure to circulating sex hormones. However, relations between MD and hormones have been inconsistent. In addition, such relations are mainly evaluated in Western populations. Therefore, we conducted a cross-sectional study in 396 cancer-free postmenopausal Korean women who had never used hormone replacement therapy. We assayed estradiol, testosterone, and sex hormone-binding globulin (SHBG) levels. We then calculated free testosterone (cFT) levels. Total and dense areas of d...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsAsian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionBreast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Use of estrogen-alone hormone replacement therapy (HRT) after oophorectomy does not increase the risk of BRCA 1-associated breast cancer, although this may not be the case for progesterone-continuing HRT, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
Conclusion Low dose of acacetin from 10^-3 μM to 1 μM promoted the proliferation of MCF-7 cells through the ERK/PI3K/AKT pathway and its downstream cyclin signaling, and this pathway is mainly mediated by the expression of ERα. PMID: 29676234 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
In a recently published paper in theAnnals of Oncology [1], Choi et al. evaluated the strength of the evidence in the literature for the association between body mass index and 20 cancers in a manner that resembles our umbrella review on the same topic [2]. We were surprised to see that there were many discrepancies between the two assessments. The current paper used a grading scheme consisting of similar criteria used in our umbrella review, but structured the grading differently without providing a justification for this choice. Our umbrella review used a grading scheme that has been extensively applied and justified in ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsMD partially mediates some of the association between HRT and breast cancer risk. The association between HRT and breast cancer seems to be stronger in women with dense breasts.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
A high-affinity subtype-selective fluorescent probe for estrogen receptor β imaging in living cells. Chem Commun (Camb). 2018 Apr 03;: Authors: Hu Z, Yang L, Ning W, Tang C, Meng Q, Zheng J, Dong C, Zhou HB Abstract Estrogen receptor β (ERβ) has recently been identified as a pharmaceutical target in hormone replacement therapy for breast cancers. However, the biological function of ERβ in disease progression remains unclear. A highly ERβ-selective fluorescent probe (FPNM) was discovered exhibiting nanomolar affinity for ERβ with an ERβ/ERα selectivity as high a...
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormone Replacement Therapy | Hormones | Reproduction Medicine | Study | Women